Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 6/20 | 0.41 |
| ▸ | CES2 | O00748 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | POLA1 | P09884 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1298659 | 0.96 | CES1 (0.44) | CES1CES2ALDH1A1TP53TSHR | |
| SCHEMBL10579259 | 0.94 | TSHR (0.42) | CES1CES2ALDH1A1TP53TSHR | |
| Ethylene SCHEMBL9299137 | 0.94 | CES1 (0.42) | CES1CES2ALDH1A1TP53TSHR | |
| Acetic Acid SCHEMBL28135566 | 0.90 | ALDH1A1 (0.43) | CES1CES2ALDH1A1TP53TSHR | |
| SCHEMBL689956 | 0.89 | CES2 (0.46) | CES1CES2ALDH1A1TSHRPOLB | |
| SCHEMBL25178527 | 0.88 | CES2 (0.48) | CES1CES2ALDH1A1TSHRPOLB | |
| SCHEMBL3503494 | 0.88 | CES2 (0.48) | CES1CES2ALDH1A1TSHRPOLB | |
| SCHEMBL7999274 | 0.88 | CES2 (0.48) | CES1CES2ALDH1A1TSHRPOLB | |
| Water SCHEMBL7997185 | 0.88 | CES2 (0.44) | CES1CES2ALDH1A1TSHRPOLB | |
| SCHEMBL25375939 | 0.88 | CES2 (0.48) | CES1CES2ALDH1A1TSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190467-A1 | Biological Polysiloxanes | VISION CRC LIMITED (AU) | 2011-08-04 | — | — | US | disclosed |
| US-20090276042-A1 | Biological Polysiloxanes | VISION CRC LIMITED (AU) | 2009-11-05 | — | — | US | disclosed |
| EP-2021399-A1 | BIOLOGICAL POLYSILOXANES | VISION CRC LIMITED (AU) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007128051-A1 | BIOLOGICAL POLYSILOXANES | VISION CRC LIMITED (AU) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090276042-A1 | Biological Polysiloxanes | PBK, B2M, CD79B | CES1 3864/4885CES2 4206/4885ALDH1A1 4364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.